C4 Therapeutics, Inc. — Director's Dealing 2020

Oct 6, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2020-10-01

Reporting Person: Prokupets Elena (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-01	Stock Option (Right to Buy)	$19.00	A	17786	Acquired	2030-09-30	Common Stock (17786)	Direct

Footnotes

F1: This option shall vest and become exercisable upon the earlier to occur of (i) October 1, 2021, and (ii) the next annual meeting of the Issuer's stockholders.